Development of the first disease activity index for eosinophilic esophagitis: update on the EEsAI in 2012

Détails

ID Serval
serval:BIB_63DCC949935D
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Institution
Titre
Development of the first disease activity index for eosinophilic esophagitis: update on the EEsAI in 2012
Titre de la conférence
Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition
Auteur(s)
Schoepfer A.M., Safroneeva E., Kuehni C., Zwahlen M., Schibli S., Mueller P., Bussmann C., Straumann A.
Adresse
Interlaken, Switzerland, September 20-21, 2012
ISBN
1424-7860
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2012
Volume
142
Série
Swiss Medical Weekly
Pages
S10
Langue
anglais
Résumé
Background and Aims: The international E EsAI s tudy g roup
is currently d eveloping the first activity index ( EEsAI) specific
for E osinophilic Esophagitis (EoE). G oal: T o develop, e valuate
and validate the EEsAI.
Methods: T he development c omprises three p hases: 1.
Selection of c andidate items ( completed); 2. Evaluation of t he
activity index i n a first patient cohort (in progress, p atient
recruitment completed); and 3. Validation in a s econd EoE
patient cohort. F ocus group interviews with patients were used
in p hase 1 to g enerate patient r eported outcomes (PRO)
according to g uidelines o f regulatory authorities (FDA a nd
EMA), whereas the section of biologic items was developed by
Delphi rounds o f international E oE experts from E urope and
North America.
Results: T he EEsAI has a modular c omposition to a ssess the
following components o f EoE activity: p atient r eported
outcomes, e ndoscopic activity, histologic activity, laboratory
activity, a nd quality of l ife (QoL). Definitions for a ll aspects o f
endoscopic and histologic appearance were e stablished by
consensus r ounds a mong E oE experts. S ymptom a ssessment
tools were c reated that t ake into account d ifferent food
consistencies as w ell as f ood avoidance and specific
processing strategies. The EEsAI i s currently e valuated in a
cohort of a dult EoE patients since M arch 2 011 (patient
recruitment completed).
Conclusions: The EEsAI standardizes outcome assessment in
EoE t rials. T he collaboration with i nternational E oE e xperts a s
well as f ollowing o f the guidelines f rom regulatory authorities
will lead to its wide applicability.
Création de la notice
14/02/2013 17:33
Dernière modification de la notice
20/08/2019 15:20
Données d'usage